|
PL170837B1
(pl)
|
1991-10-18 |
1997-01-31 |
Monsanto Co |
S rod ek g r zybobó j c zy PL PL PL PL PL PL
|
|
SE9703407D0
(sv)
*
|
1997-09-19 |
1997-09-19 |
Astra Ab |
New use
|
|
SE9802073D0
(sv)
|
1998-06-11 |
1998-06-11 |
Astra Ab |
New use
|
|
GB9825554D0
(en)
*
|
1998-11-20 |
1999-01-13 |
Smithkline Beecham Spa |
Novel Compounds
|
|
US7037922B1
(en)
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
WO2000058313A1
(en)
|
1999-03-29 |
2000-10-05 |
Neurogen Corporation |
4-substituted quinoline derivatives as gaba receptor ligands
|
|
AU4802500A
(en)
|
1999-04-26 |
2000-11-10 |
Neurogen Corporation |
2-aminoquinolinecarboxamides: neurokinin receptor ligands
|
|
US20040152726A1
(en)
*
|
2001-04-11 |
2004-08-05 |
Carlo Farina |
Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
|
|
AU2002259147A1
(en)
*
|
2001-05-08 |
2002-11-18 |
Schering Corporation |
Use of neurokinin receptor antagonists to treat androgen-dependent diseases
|
|
ATE477268T1
(de)
|
2003-01-28 |
2010-08-15 |
Ironwood Pharmaceuticals Inc |
Zusammensetzungen zur behandlung von magen-darm- störungen
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
GB0303086D0
(en)
*
|
2003-02-11 |
2003-03-19 |
Merck Sharp & Dohme |
New compounds
|
|
GB0419192D0
(en)
|
2004-08-27 |
2004-09-29 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
BRPI0517567A
(pt)
*
|
2004-11-09 |
2008-06-17 |
Smithkline Beecham Corp |
composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
|
|
GB0425077D0
(en)
*
|
2004-11-12 |
2004-12-15 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0515580D0
(en)
|
2005-07-29 |
2005-09-07 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
JP2009504641A
(ja)
*
|
2005-08-11 |
2009-02-05 |
アストラゼネカ・アクチエボラーグ |
Ｎｋ−３受容体の調節剤としてのアルキルピリジルキノリン
|
|
AR057130A1
(es)
|
2005-09-21 |
2007-11-14 |
Astrazeneca Ab |
Quinolinas de alquilsulfoxido y una composicion farmaceutica
|
|
TW201018662A
(en)
|
2005-12-12 |
2010-05-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
MX2009013293A
(es)
|
2007-06-04 |
2010-02-15 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
|
|
JP2010540553A
(ja)
*
|
2007-09-28 |
2010-12-24 |
グラクソスミスクライン エルエルシー |
グリコーゲンホスホリラーゼ阻害剤化合物及びその医薬組成物
|
|
MX2010003440A
(es)
*
|
2007-09-28 |
2010-04-21 |
Glaxosmithkline Llc |
Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
KR20170091783A
(ko)
|
2008-12-31 |
2017-08-09 |
알데릭스, 인코포레이티드 |
체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
AU2013304812B2
(en)
|
2012-08-21 |
2016-06-09 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
|
SMT201900386T1
(it)
|
2013-04-12 |
2019-09-09 |
Ardelyx Inc |
Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
|
|
WO2014170648A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
EA201592263A1
(ru)
|
2013-06-05 |
2016-05-31 |
Синерджи Фармасьютикалз, Инк. |
Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
AU2018205400C1
(en)
|
2017-01-09 |
2026-01-15 |
Ardelyx, Inc. |
Compounds useful for treating gastrointestinal tract disorders
|
|
JP2020505333A
(ja)
|
2017-01-09 |
2020-02-20 |
アルデリックス， インコーポレイテッド |
Ｎｈｅ媒介性アンチポートの阻害薬
|